ASCO 2023 Prostate Cancer - Results from #20

Viewing 21-40 of 84 articles

ASCO 2023: Discussant: DDR and PARP Inhibition: What's the Damage?

ASCO 2023: PSMAddition: A Phase 3 Trial to Compare Treatment with 177Lu-PSMA-617 + Standard of Care and Standard of Care Alone in Patients with mHSPC

ASCO 2023: TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + ENZA as First-Line Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Harboring Homologous Recombination Repair (HRR) Gene Alterations

ASCO 2023: Presence of Somatic/Germline Homologous Recombination Repair Mutations and Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Receiving First‑line Treatment Stratified by BRCA Status

ASCO 2023: LuPARP: Phase 1 Trial of 177Lu-PSMA-617 and Olaparib in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)

ASCO 2023: Discussant: Hitting the Sweet Spot with Radiation and Androgen Deprivation

ASCO 2023: Real-World Safety and Effectiveness of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated in the US: The Non-Interventional REASSURE Study

ASCO 2023: Talazoparib plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Safety Analyses from the Randomized, Placebo-Controlled, Phase 3 TALAPRO-2 Study

ASCO 2023: Outcomes by Complete Response to First-Line Pembrolizumab or Platinum-Based Chemotherapy in Advanced Urothelial Carcinoma in KEYNOTE-361

ASCO 2023: Final Results from Phase I Study of PSCA-Targeted CAR T Cells in Patients with mCRPC

ASCO 2023: Prognostic Impact of PSA Nadir (N) ≥0.1 ng/mL Within 6 Months After Completion of Radiotherapy for Localized Prostate Cancer: An Individual Patient-Data Analysis of Randomized Trials from the ICECaP Collaborative

ASCO 2023: AI-Derived Digital Pathology Biomarker Predicts Benefit of Long-Term ADT with Radiotherapy in Localized High-Risk Prostate Cancer

ASCO 2023: Phase I Dose-Escalation Results of PSMA Targeted Radionuclide Therapy with Alpha-Radiolabeled Antibody 225Ac-J591 and Beta-Radioligand 177Lu-PSMA I&T

ASCO 2023: Impact of Histology on the Efficacy and Safety of Pembrolizumab Monotherapy for Advanced Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials

ASCO 2023: Discussant: Looking Ahead: Novel Agents in Castration-Resistant Prostate Cancer

ASCO 2023: Estimated Net Benefit of Avelumab + Best Supportive Care (BSC) vs BSC Alone for Patients with Advanced Urothelial Carcinoma Using a Quality-Adjusted Time Without Cancer Symptoms or Toxicity (Q-TWiST) Analysis

ASCO 2023: Prostate Irradiation in Men with De Novo, Low-Volume, Metastatic, Castration-Sensitive Prostate Cancer (mCSPC): Results of PEACE-1, a Phase 3 Randomized Trial with a 2x2 Design

ASCO 2023: Efficacy and Safety of Darolutamide in Chinese Patients with mHSPC: A Subpopulation Analysis of the Phase 3 ARASENS Study

ASCO 2023: Discussant: Right Treatment, Right Setting for Systemic Therapy

ASCO 2023: Discussant: Quality in the Context of Quantity: Evaluating Treatment Intensification

1
2
3
4
5